Cocrystal Pharma
COCP
14 hedge funds and large institutions have $1.57M invested in Cocrystal Pharma in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
55% more capital invested
Capital invested by funds: $1.01M → $1.57M (+$557K)
0.46% less ownership
Funds ownership: 7.1% → 6.63% (-0.46%)
13% less funds holding
Funds holding: 16 → 14 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.58K |
| 2 |
Renaissance Technologies
New York
|
+$7.41K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$113 |
| 4 |
Morgan Stanley
New York
|
+$57 |
| 5 |
AWM
Activest Wealth Management
Aventure,
Florida
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28.4K |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.36K |
| 5 |
VL
Vima LLC
Troy,
Michigan
|
-$461 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $642K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $302K | +$7.41K | +3,800 | +3% |
|
3
BlackRock
New York
| $172K | – | – | – |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $151K | +$8.58K | +4,400 | +7% |
|
|
5
Morgan Stanley
New York
| $138K | +$57 | +29 | +0% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $58.4K | -$52.8K | -27,078 | -52% |
|
|
7
State Street
Boston,
Massachusetts
| $47.9K | -$7.6K | -3,900 | -16% |
|
8
Northern Trust
Chicago,
Illinois
| $28.4K | -$70 | -36 | -0.3% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $21K | +$113 | +58 | +0.6% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $8.58K | -$7.36K | -3,775 | -51% |
|
11
JP Morgan Chase
New York
| $997 | -$224 | -115 | -21% |
|
|
NL
12
NVWM LLC
Yardley,
Pennsylvania
| $196 | – | – | – |
|
|
AWM
13
Activest Wealth Management
Aventure,
Florida
| $2 | +$2 | +1 | New |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$28.4K | -20,258 | Closed |
|
|
VL
15
Vima LLC
Troy,
Michigan
| – | -$461 | -231 | Closed |
|
16
Wells Fargo
San Francisco,
California
| – | -$130 | -93 | Closed |
|
COCP Hedge Fund Activity: Q2 2024 in Review
14 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q2 2024, worth a combined $1.57M — up 55% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of COCP and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $8.58K. The largest seller was Susquehanna International Group, cutting an estimated $52.8K.
- 14 institutional investors held Cocrystal Pharma (COCP) as of Q2 2024, down from 16 in Q1 2024.
- Funds reported $1.57M of Cocrystal Pharma stock for Q2 2024, up 55% quarter-over-quarter.
- 1 fund opened new Cocrystal Pharma positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Cocrystal Pharma buyer in Q2 2024 was Geode Capital Management, an estimated $8.58K added.
- The largest Cocrystal Pharma seller in Q2 2024 was Susquehanna International Group, an estimated $52.8K sold.
Based on aggregated 13F filings for Q2 2024.